Day One Bio Day One Bio

Scientific Publications

Contributing to and advancing the scientific dialogue.

October 2021

FIRELIGHT: DAY101-102a, a phase 2 subprotocol of DAY101 monotherapy for patients with recurrent, progressive, or refractory solid tumors with an activating BRAF gene fusion

Mehmi I, Lourdes L, Cornelio I, Blackman S, Barry E, Drexel M, Kondo A, Kummar S 18th International Congress of the Society for Melanoma Research

October 2021

Prolonged complete response to the pan-RAF inhibitor DAY101 in a patient with an NRAS-mutated acral lentiginous melanoma

Medina T, Barry E, Raju S, Blackman S, Gonzalez R 18th International Congress of the Society for Melanoma Research

See our progress in motion.

See open jobs

You are now leaving the Day One Biopharmaceuticals Corporate Website

You will now be redirected to the requested website. Please confirm that you want to proceed.

Yes No